Effectiveness of the P2X3 Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study Authors: Yoshihisa Ishiura, Shosaku Nomura, Noriyuki Ohkura, Johsuke Hara, Masaki Fujimura, Tomoki Ito Published: 2026 ABSTRACT BackgroundAtopic cough, arising from hyperresponsiveness of afferent airway C-fibers, is common, and cough is one of the commonest reasons for referral to respiratory clinic. Gefapixant is a first-in-class P2X3 receptor antagonist recently approved for use in patients with refractory cough to inhibit airway C-fiber activation. We conducted this study to investigate the clinical effect of gefapixant in patients with refractory atopic cough that responded only partially to azelastine monotherapy.MethodsThis was a single-center retrospective observational study. Patients with refractory atopic cough received gefapixant. Collected retrospectively from medical records, data included cough symptom questionnaire responses and results from respiratory function tests, cough reflex sensitivity tests, and blood tests.ResultsData from 23 patients with refractory atopic cough were included in this study. Spirometry parameters, fractional exhaled nitric oxide levels, peripheral eosinophil counts, and IgE levels were unchanged after gefapixant treatment. Scores for the cough severity visual analog scale and Leicester cough questionnaire significantly improved after treatment with gefapixant (both p<0.01). Cough reflex sensitivity to inhaled capsaicin also significantly improved after treatment with gefapixant (p<0.01).ConclusionThe P2X3 antagonist gefapixant appeared to improve patient-reported symptoms and cough reflex hypersensitivity in a retrospective cohort of patients with refractory atopic cough. These findings suggest P2X3 antagonists may be a treatment option for refractory atopic cough, possibly through possibly through reducing hypersensitivity of airway C fibers. Introduction Cough is the commonest symptom in primary care worldwide.1 It adversely affects quality of life, sleep, work, and social activities, imposing a societal burden. Furthermore, when chronic, cough is associated with a substantial disease burden.2,3 Meta-analyses estimate the global prevalence of chronic cough to be approximately 10%.1 It is therefore important to investigate more effective treatments for refractory chronic cough (RCC), in particular, to improve patient quality of life.1–3 Gefapixant is a first-in class P2X3 receptor antagonist recently approved for use in patients with RCC. It reduces the cough response by reducing ATP-drive sensitization of sensory nerve transmission, especially C-fibers.4,5 However, little is known about which RCC-presenting disease entities can be effectively treated with gefapixant. Atopic cough is a common cause of chronic and subacute cough; it is caused by hypersensitivity of airway sensory C-fibers and can easily lead to RCC.6–13 We reported a patient with refractory atopic cough who received gefapixant and exhibited a marked improvement in symptomatic cough with airway cough reflex hypersensitivity despite only partial efficacy of numerous other drugs.14 We therefore conducted this study to investigate the clinical effectiveness of gefapixant as a treatment option for patients with refractory atopic cough as a retrospective cohort study. Methods Study Design and Patient Population This was a single-center retrospective observational pilot study. It includes data from patients with refractory atopic cough who visited Kansai Medical University Medical Center from June 2022 to September 2025 and had only partial responses to azelastine 2 mg twice daily. The patients received additional treatment with gefapixant for refractory atopic cough. Each patient was tested at the same time each day. Control measurement of the capsaicin cough threshold was carried out before starting treatment with gefapixant. A gefapixant tablet (45mg) was taken orally twice daily for 4 weeks and at 8.00 a.m. on the test day. The dose tested in this study was the usual dose recommended for refractory chronic cough, based on Phase II and III studies. Respiratory function tests, FeNO, blood samples and each symptom score were measured before capsaicin challenge to assess the effect of this treatment regimens. Blood samples were collected to measure the leukocyte count and the total serum IgE level by a radioimmunosorbent test (RIST, Pharmacia, Uppsala, Sweden). Because this study analyzed data from patients who were able to continue outpatient treatment, most patients who experienced taste disturbance were excluded as they chose not to return to the clinic. Data from 23 patients with a mean age of 62.2 ± 19.3 years (± standard deviation, SD) (range 22–87 years) were included in this study. All patients were lifetime nonsmokers or former smokers and had no history of viral infection for at least 4 weeks prior to this study. Data were collected retrospectively from medical records and included cough symptom questionnaire scores, blood examination test results, respiratory function test results, fractional exhaled nitric oxide (FeNO), and cough reflex sensitivity test results. The cough severity visual analog scale (VAS) was used to assess patient-reported cough burden at each visit (range, 0–100; higher score = greater severity). Other cough symptoms affecting quality of life were assessed using the Leicester Cough Questionnaire (LCQ) score (range, 3–21; lower score = greater severity).15 All patients had previously received treatment with 4 mg/day of azelastine, a histamine H1 receptor antagonist, and some had also received inhaled steroids (see Table 1), but these treatments achieved only partial success and were deemed insufficient. Therefore, additional treatment with gefapixant, a P2X3 antagonist, was indicated for these patients with refractory atopic cough. Re-evaluation of each parameter was conducted before and after 4 weeks of administration of gefapixant 45 mg twice daily.Table 1Patient CharacteristicsAge (Years)62.2 ± 19.3, Range 22–87Gender (male/female)10/13Body mass index (kg/m2)24.1 ± 5.2Treatment of azelastine (with/without)23/0Treatment of ICS (with/without)10/13Brinchodilkator response# (%)3.6 ± 3.2Notes: #The bronchodilator response refers to the percentage increase in forced expiratory volume in one second (FEV1) from baseline following inhalation of 300 μg of salbutamol sulphate. Data are presented as mean ± standard deviation.Abbreviation: ICS, inhaled corticosteroid. Table 1Patient CharacteristicsAge (Years)62.2 ± 19.3, Range 22–87Gender (male/female)10/13Body mass index (kg/m2)24.1 ± 5.2Treatment of azelastine (with/without)23/0Treatment of ICS (with/without)10/13Brinchodilkator response# (%)3.6 ± 3.2Notes: #The bronchodilator response refers to the percentage increase in forced expiratory volume in one second (FEV1) from baseline following inhalation of 300 μg of salbutamol sulphate. Data are presented as mean ± standard deviation.Abbreviation: ICS, inhaled corticosteroid. Patient Characteristics Notes: #The bronchodilator response refers to the percentage increase in forced expiratory volume in one second (FEV1) from baseline following inhalation of 300 μg of salbutamol sulphate. Data are presented as mean ± standard deviation. Abbreviation: ICS, inhaled corticosteroid. Ethical Considerations This study was registered at the University Hospital Medical Information Network (000058428) and approved by the Ethics Committee of Kansai Medical University (No. 2025122, approved on August 25, 2025). It was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Written informed consent was waived owing to the retrospective nature of the study. Diagnosis The diagnosis of atopic cough was conducted following the Japanese guidelines for the management of cough8 and criteria included: (1) persistent non-productive cough without wheezing and dyspnea for 8 weeks or longer, (2) poor response to bronchodilators, (3) one or more findings suggesting atopic predisposition or eosinophilia in induced sputum, and (4) cough improvement with a histamine H1 receptor antagonist and/or corticosteroids. Furthermore, based on our previous studies, we conducted additional examinations to make the diagnosis of atopic cough more reliable.10–13,16 We used the additional criteria of (5) no bronchial reversibility, defined as less than a 10% increase in forced expiratory volume in 1 second (FEV1) after inhalation of 300 µg of salbutamol sulfate; (6) increased cough reflex sensitivity, defined as a capsaicin concentration eliciting five or more coughs of 3.9 µM or less; (7) no abnormal findings that could cause cough on chest radiographs; and (8) normal FEV1 (80% of predicted value), forced vital capacity (FVC) (80% of predicted value), and FEV1/FVC ratio (70%). When all these criteria were satisfied, an accurate and definitive diagnosis of atopic cough was made. Pulmonary Function, Cough Reflex Sensitivity, and Bronchial Reversibility Pulmonary function, cough reflex sensitivity, and bronchial reversibility were measured, in that order, within 1 month of the first visit, before conducting this study. The FVC, FEV1, and flow-volume curve were measured using a dry wedge spirometer (Chestac 11, Chest Co., Tokyo, Japan). Spirometry was performed and evaluated according to the American Thoracic Society criteria and our previous study.17 Cough reflex sensitivity was assessed using capsaicin provocation testing.18 Capsaicin (30.5 mg) was dissolved in Tween 80 (1 mL) and ethanol (1 mL), and then in physiological saline (8 mL) to create a stock solution of 1 × 10⁻2 M, and stored at −20°C. The solution was diluted with physiological saline to create a series of solutions, starting at a concentration of 0.49 µM and increasing two-fold up to 1000 µM. Each subject inhaled a control solution of physiological saline, followed by the capsaicin solution at progressively increasing concentrations. The solutions were inhaled for 15 seconds every 60 seconds by tidal mouth breathing while wearing a nose clip, using a Bennett Twin Nebulizer (3012–60cc, Puritan Bennett, Carlsbad, CA, USA). Increasing concentrations were inhaled until five or more coughs were elicited. The nebulizer output was 0.21 mL/min. A medical technician in our pulmonary function laboratory counted the number of capsaicin-induced coughs in a blinded fashion. The cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs. To assess eosinophilic airway inflammation, FeNO was measured using a commercially available device (NIOX MINO™; Aerocrine, Stockholm, Sweden) prior to any forced expiratory maneuvers according to our previous study.19 Data Analysis Capsaicin cough threshold values and total serum IgE levels were transformed to logarithmic values and expressed as the geometric mean with the geometric SD of the mean. Other data obtained in the study are presented as the mean ± SD. The cough severity VAS scores and LCQ scores before and after gefapixant administration were compared using the Wilcoxon signed-rank test. Other data before and after gefapixant administration were also compared using the Wilcoxon signed-rank test. Values of p < 0.05 were considered statistically significant. All analyses were performed using StatView 4.5J software (Abacus Concepts, Berkeley, CA, USA), without using artificial intelligence. Results The respiratory function results obtained by spirometry are shown in Table 2. Spirometry parameters before treatment with gefapixant were within the normal range as demonstrated in our previous study,10–14,16 and did not significantly change after additional 4 weeks treatment with gefapixant. These findings suggest that coughing in this disorder, named “atopic cough”, is caused by hypersensitivity of airway C-fibers and is unrelated to small airway obstructions. FeNO levels before treatment with gefapixant were also within the normal range as demonstrated in our previous study,10–14,16 and did not significantly change after additional 4 weeks treatment with gefapixant. These findings also suggest that coughing in this disorder is unrelated to eosinophilic inflammation. VAS scores, LCQ scores, cough sensitivity to inhaled capsaicin and blood examination results 4 weeks after treatment with gefapixant are shown in Table 3. Cough severity VAS scores and LCQ scores significantly improved after 4 weeks treatment with gefapixant (both p<0.01; Figures 1 and 2). The cough threshold to inhaled capsaicin before treatment with gefapixant was 1.65 ± 5.90 μmol/L, indicating cough reflex hypersensitivity as shown in our previous study.10–14,16 The cough threshold to inhaled capsaicin significantly improved after treatment with gefapixant (p<0.01; Figure 3), indicating that improvement of symptom scores was the result of reducing hypersensitivity of airway C fibers. Peripheral eosinophil counts and IgE levels were unchanged after gefapixant treatment. Our previous study demonstrated that Th2 cytokine inhibition reduces peripheral eosinophil counts and IgE levels accompanied by the improvement of cough threshold to inhaled capsaicin.13 These findings also suggest that the improvement of the symptom scores in refractory atopic cough is caused by the reduction of the hypersensitivity of airway C fibers, independent of airway eosinophilic inflammation. Adverse events associated with gefapixant were assessed at the first follow-up visit, within two weeks after the start of treatment. Some patients experienced taste disturbances, but these resolved within a few days of gefapixant discontinuation.Table 2Spirometry Parameters After Each TreatmentAzelastineAzelastine + GefapixantP-valueSpirometry parametersFVC (L)2.76 ± 0.772.71 ± 0.700.46FVC (as % predicted)92.5 ± 18.592.0 ± 22.40.58FEV1 (L)2.19 ± 0.692.13 ± 0.690.52FEV1 (as % predicted)90.9 ± 21.490.7 ± 22.80.90FEV1 /FVC (%)78.9 ± 6.4877.8 ± 8.010.57PEF (L/S)6.28 ± 2.085.91 ± 2.270.63PEF (as % predicted)82.3 ± 24.378.8 ± 24.50.69MEF50 (L/S)2.84 ± 1.282.68 ± 1.440.66MEF50 (as % predicted)85.9 ± 32.381.5 ± 36.00.71FeNO (ppb)11.0 ± 5.0911.4 ± 5.480.86Notes: Data are presented as mean ± standard deviation.Abbreviations: FVC, forced vital capacity; FEV1, forcedexpiratory volume in 1 second; PEF, peal expiratory flow; MEF50, maximum expiratory flow rate at 50% force vital capacity; FeNO, fractional exhaled nitric acid. Table 3Capsaicin Cough Threshold, VAS, LCQ and Blood Examination After Each TreatmentAzelastineAzelastine + GefapixantP-valueCapsaicin cough threshold (μmol/L)1.65 ± 5.903.90 ± 5.250.0024Cough severity VAS score (mm)53.2 ± 23.324.6 ± 22.40.00031LCQ total13.0± 3.7016.6 ± 3.550.0021 LCQ physical4.36 ± 1.105.35 ± 1.170.0021 LCQ psychological4.22 ± 1.565.54 ± 1.310.0015 LCQ social4.23 ± 1.575.69 ± 1.230.0014Serum total IgE (IU/mL)46.6 ± 5.9242.0 ± 5.990.12Peripheral eosinophil count (/μL)195.1 ± 202.9171.5 ± 151.90.69Notes: Data are presented as the mean ± standard deviation for the cough severity VAS score, LCQ and peripheral eosinophil count, and as the geometric mean (geometric mean ± standard deviation) for the capsaicin cough threshold and IgE.Abbreviations: VAS, visual analogue scale; LCQ, Leicester cough questionnaire. Figure 1Individual visual analog scale scores for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by Wilcoxon signed-rank test.A paired dot plot compares cough visual analog scale scores for Azelastine and Azelastine plus Gefapixant treatments. The x-axis lists these treatments, while the y-axis shows Cough VAS scores from 0 to 80 millimeters. Each subject is represented by a circle at each treatment, connected by lines. Open and closed circles are used, with asterisks above the plot. For Azelastine, scores are around 82, 81, 80, 73, 71, 67, 53, 52, 51, 41, 41, 32, 31, 22, 21 and 12 millimeters, summarized near 53 millimeters. For Azelastine plus Gefapixant, scores are around 76, 72, 52, 44, 42, 32, 23, 21, 12, 11, 2 and 0 millimeters, with clusters near 10-12 and 20-23 millimeters, summarized near 23 millimeters. Most lines slope downward from Azelastine to Azelastine plus Gefapixant, showing significant drops from about 80 to 0-12 millimeters. A few lines slope upward, such as from 67 to 76 millimeters and 41 to 52 millimeters.A paired dot plot of cough visual analog scale scores, mostly decreasing after combination therapy. Figure 2Individual Leicester cough questionnaire scores for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by Wilcoxon signed-rank test.Four paired dot plots compare LCQ scores for Azelastine alone and combined with Gefapixant across total, physical, psychological and social categories. Each plot shows patient data with lines connecting scores for both treatments. Open and closed circles denote different patient groups and a thick horizontal bar appears in each treatment column. Double asterisks are noted above each plot. In the LCQ total plot, scores range from 5 to 20, with most lines rising from Azelastine (7-19) to Azelastine plus Gefapixant (10-21). The LCQ physical plot shows scores from 1 to 7, with most lines increasing from Azelastine (2-6) to Azelastine plus Gefapixant (3-7). The LCQ psychological and social plots also range from 1 to 7, with many lines rising from Azelastine (1-7) to Azelastine plus Gefapixant (3-7). Overall, the combination therapy often results in higher LCQ scores.A four-plot paired dot chart showing Leicester cough questionnaire scores for two treatments.Abbreviations: LCQ, Leicester cough questionnaire; LCQ total, total LCQ score; LCQ physical, LCQ physical domain score; LCQ psychological, LCQ psychological domain score; and LCQ social, LCQ social domain score. Figure 3Individual capsaicin cough threshold data for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by paired t-tests transformed to logarithmic values.A scatterplot with lines shows capsaicin cough threshold. The y-axis is labeled Capsaicin cough threshold (micromolar) with logarithmic ticks: 0.1, 1, 10, 100, 1000. The x-axis has two categories: Azelastine and Azelastine plus Gefapixant. Each subject is represented by circles at each category, connected by lines; circles are both open and closed. Thick horizontal bars indicate central tendency for each category. A double asterisk is above the highest right-side point. Plotted values include Azelastine points around 0.5, 1, 2, 3, 4, 5 and Azelastine plus Gefapixant points at 0.5, 1, 2, 4, 5, 8, 10, 20, 40, 80, 300.A paired scatterplot showing capsaicin cough threshold for azelastine and azelastine plus gefapixant. Table 2Spirometry Parameters After Each TreatmentAzelastineAzelastine + GefapixantP-valueSpirometry parametersFVC (L)2.76 ± 0.772.71 ± 0.700.46FVC (as % predicted)92.5 ± 18.592.0 ± 22.40.58FEV1 (L)2.19 ± 0.692.13 ± 0.690.52FEV1 (as % predicted)90.9 ± 21.490.7 ± 22.80.90FEV1 /FVC (%)78.9 ± 6.4877.8 ± 8.010.57PEF (L/S)6.28 ± 2.085.91 ± 2.270.63PEF (as % predicted)82.3 ± 24.378.8 ± 24.50.69MEF50 (L/S)2.84 ± 1.282.68 ± 1.440.66MEF50 (as % predicted)85.9 ± 32.381.5 ± 36.00.71FeNO (ppb)11.0 ± 5.0911.4 ± 5.480.86Notes: Data are presented as mean ± standard deviation.Abbreviations: FVC, forced vital capacity; FEV1, forcedexpiratory volume in 1 second; PEF, peal expiratory flow; MEF50, maximum expiratory flow rate at 50% force vital capacity; FeNO, fractional exhaled nitric acid. Spirometry Parameters After Each Treatment Notes: Data are presented as mean ± standard deviation. Abbreviations: FVC, forced vital capacity; FEV1, forcedexpiratory volume in 1 second; PEF, peal expiratory flow; MEF50, maximum expiratory flow rate at 50% force vital capacity; FeNO, fractional exhaled nitric acid. Table 3Capsaicin Cough Threshold, VAS, LCQ and Blood Examination After Each TreatmentAzelastineAzelastine + GefapixantP-valueCapsaicin cough threshold (μmol/L)1.65 ± 5.903.90 ± 5.250.0024Cough severity VAS score (mm)53.2 ± 23.324.6 ± 22.40.00031LCQ total13.0± 3.7016.6 ± 3.550.0021 LCQ physical4.36 ± 1.105.35 ± 1.170.0021 LCQ psychological4.22 ± 1.565.54 ± 1.310.0015 LCQ social4.23 ± 1.575.69 ± 1.230.0014Serum total IgE (IU/mL)46.6 ± 5.9242.0 ± 5.990.12Peripheral eosinophil count (/μL)195.1 ± 202.9171.5 ± 151.90.69Notes: Data are presented as the mean ± standard deviation for the cough severity VAS score, LCQ and peripheral eosinophil count, and as the geometric mean (geometric mean ± standard deviation) for the capsaicin cough threshold and IgE.Abbreviations: VAS, visual analogue scale; LCQ, Leicester cough questionnaire. Capsaicin Cough Threshold, VAS, LCQ and Blood Examination After Each Treatment Notes: Data are presented as the mean ± standard deviation for the cough severity VAS score, LCQ and peripheral eosinophil count, and as the geometric mean (geometric mean ± standard deviation) for the capsaicin cough threshold and IgE. Abbreviations: VAS, visual analogue scale; LCQ, Leicester cough questionnaire. Individual visual analog scale scores for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by Wilcoxon signed-rank test. Individual Leicester cough questionnaire scores for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by Wilcoxon signed-rank test. Individual capsaicin cough threshold data for patients with refractory atopic cough receiving azelastine monotherapy and after receiving azelastine plus gefapixant combination therapy. Closed circles represent patients receiving inhaled steroid therapy and open circles represent patients without inhaled steroid therapy. **p < 0.01, determined by paired t-tests transformed to logarithmic values. Discussion Our results demonstrate that gefapixant, a P2X3 antagonist, improved patient-reported symptoms and cough reflex hypersensitivity in our cohort of patients with refractory atopic cough in a single-center retrospective observational pilot study. These findings imply the potential of P2X3 antagonist as therapeutic options for refractory atopic cough. Atopic cough is commonly the underlying cause of chronic and subacute cough, which can persist for years when refractory,6,7 comprising an important clinical problem.9,12,14 More potent therapies for refractory atopic cough are required because histamine H1 receptor antagonists fail to adequately control cough in approximately 40% of cases.12 Atopic cough is also difficult to differentiate from cough-variant asthma because both disorders present with chronic eosinophilic nonproductive cough.8,9 However, these two diseases should be carefully distinguished because they require different treatments,8,9,20 and misdiagnosis can easily lead to refractory cough. The clinical features of atopic cough include bronchodilator resistance, because bronchodilator therapy mediates cough-suppressing effects only in cough-variant asthma.8,9,20 The fundamental features of atopic cough include eosinophilic inflammation of the central airways and increased cough reflex sensitivity,10 whereas those of cough-variant asthma are eosinophilic inflammation of the peripheral airways with mildly increased bronchial responsiveness.21,22 Atopic cough presents with lower FeNO levels and cough-variant asthma is associated with increased FeNO levels.11 Atopic cough is thought to arise from hyperresponsiveness of afferent airway C-fibers, with cough-variant asthma thought to arise from afferent Aδ-fibers hyperresponsiveness.8,9,20,23 Accurate differential diagnosis and effective treatment of atopic cough are necessary to prevent the condition becoming refractory. Gefapixant, by inhibiting the P2X3 pathway, blocks adenosine triphosphate-dependent ion channels, thereby suppressing airway C-fiber activation.24 Given the known mechanism of action of gefapixant, we suspect that reducing hypersensitivity of airway C fibers may be driving the effectiveness of gefapixant for refractory atopic cough induced by afferent airway C-fiber hyperresponsiveness. Thus, the treatment of RCC with gefapixant should be investigated in large-scale prospective studies to validate our findings and establish if airway sensory C-fiber activation represents a treatable trait of refractory atopic cough that could be targeted through blocking the P2X3 pathway. The present study had several limitations. First, although additional treatment with gefapixant demonstrated a statistically significant improvement in symptom scores and cough reflex hypersensitivity, all patients had already received azelastine, a histamine H1 antagonist. The clinical effect observed in this study cannot be definitively attributed to gefapixant and may reflect an interaction between histamine H1 antagonism and P2X3 antagonism. Further studies investigating administration of gefapixant alone would be required to elucidate the effectiveness of P2X3 inhibition for refractory atopic cough. Second, this study was conducted retrospectively, using data from patients who continued outpatient treatment. We could not conduct follow-up surveys for patients who discontinued outpatient treatment. As a result, we could not distinguish between patients who stopped visiting our clinic owing to adverse effects like taste disturbance and those who did not return because they achieved significant improvement. Taste disturbance is an important adverse effect of P2X3 inhibitors; to achieve sustained treatment and reduce treatment discontinuation, it will be important to develop new drugs that do not cause taste disturbance.25 Third, atopic cough is widely recognized in Japan as a common cause of chronic and subacute cough;6,7 however, this disease entity may not be well recognized in other countries. We believe our results support the importance of atopic cough caused by airway C-fiber hyperresponsiveness, which we hope will become recognized in more countries. Furthermore, while it is important to assess cough frequency using objective methods, we did not evaluate cough frequency in this study. Succeeding study may be required to assess the effect of gefapixant on cough frequency. Finally, measurement of cough reflex sensitivity via a capsaicin challenge test to assess airway C-fiber hyperresponsiveness is not routine clinical practice. However, this test is important to distinguish atopic cough from cough-variant asthma caused by hyperresponsiveness of sensory Aδ-fibers. Cough reflex sensitivity testing should be utilized more widely in clinical practice to distinguish atopic cough from cough-variant asthma to ensure accurate differential diagnosis and facilitate effective treatment. Conclusions In our cohort, treatment with the P2X3 antagonist gefapixant improved patient-reported symptoms and cough reflex hypersensitivity in patients with refractory atopic cough in this retrospective and uncontrolled study. These findings support the potential role of P2X3 antagonists in a subgroup of RCC caused by atopic cough. Larger prospective randomized and placebo controlled studies are required to confirm the clinical effect of P2X3 antagonists in patients with refractory atopic cough, especially those without prior histamine H1 antagonism.